Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.

Ian D. Meng, David Dodick, Michael H. Ossipov, Frank Porreca

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Medication overuse headache (MOH) is a clinical concern in the management of migraine headache. MOH arises from the frequent use of medications used for the treatment of a primary headache. Medications that can cause MOH include opioid analgesics as well as formulations designed for the treatment of migraine, such as triptans, ergot alkaloids, or drug combinations that include caffeine and barbiturates. Gathering evidence indicates that migraine patients are more susceptible to development of MOH, and that prolonged use of these medications increases the prognosis for development of chronic migraine, leading to the suggestion that similar underlying mechanisms may drive both migraine headache and MOH. In this review, we examine the link between several mechanisms that have been linked to migraine headache and a potential role in MOH. For example, cortical spreading depression (CSD), associated with migraine development, is increased in frequency with prolonged use of topiramate or paracetamol. Increased CGRP levels in the blood have been linked to migraine and elevated CGRP can be casued by prolonged sumatriptan exposure. Possible mechanisms that may be common to both migraine and MOH include increased endogenous facilitation of pain and/or diminished diminished endogenous pain inhibition. Neuroanatomical pathways mediating these effects are examined.

Original languageEnglish (US)
Pages (from-to)851-860
Number of pages10
JournalCephalalgia
Volume31
Issue number7
DOIs
StatePublished - May 2011

Fingerprint

Secondary Headache Disorders
Migraine Disorders
Cortical Spreading Depression
Ergot Alkaloids
Tryptamines
Sumatriptan
Pain
Barbiturates
Drug Combinations
Acetaminophen
Caffeine
Opioid Analgesics
Headache

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pathophysiology of medication overuse headache : insights and hypotheses from preclinical studies. / Meng, Ian D.; Dodick, David; Ossipov, Michael H.; Porreca, Frank.

In: Cephalalgia, Vol. 31, No. 7, 05.2011, p. 851-860.

Research output: Contribution to journalArticle

Meng, Ian D. ; Dodick, David ; Ossipov, Michael H. ; Porreca, Frank. / Pathophysiology of medication overuse headache : insights and hypotheses from preclinical studies. In: Cephalalgia. 2011 ; Vol. 31, No. 7. pp. 851-860.
@article{bdfb6ddb878c460fb67083ba4f75998c,
title = "Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.",
abstract = "Medication overuse headache (MOH) is a clinical concern in the management of migraine headache. MOH arises from the frequent use of medications used for the treatment of a primary headache. Medications that can cause MOH include opioid analgesics as well as formulations designed for the treatment of migraine, such as triptans, ergot alkaloids, or drug combinations that include caffeine and barbiturates. Gathering evidence indicates that migraine patients are more susceptible to development of MOH, and that prolonged use of these medications increases the prognosis for development of chronic migraine, leading to the suggestion that similar underlying mechanisms may drive both migraine headache and MOH. In this review, we examine the link between several mechanisms that have been linked to migraine headache and a potential role in MOH. For example, cortical spreading depression (CSD), associated with migraine development, is increased in frequency with prolonged use of topiramate or paracetamol. Increased CGRP levels in the blood have been linked to migraine and elevated CGRP can be casued by prolonged sumatriptan exposure. Possible mechanisms that may be common to both migraine and MOH include increased endogenous facilitation of pain and/or diminished diminished endogenous pain inhibition. Neuroanatomical pathways mediating these effects are examined.",
author = "Meng, {Ian D.} and David Dodick and Ossipov, {Michael H.} and Frank Porreca",
year = "2011",
month = "5",
doi = "10.1177/0333102411402367",
language = "English (US)",
volume = "31",
pages = "851--860",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Pathophysiology of medication overuse headache

T2 - insights and hypotheses from preclinical studies.

AU - Meng, Ian D.

AU - Dodick, David

AU - Ossipov, Michael H.

AU - Porreca, Frank

PY - 2011/5

Y1 - 2011/5

N2 - Medication overuse headache (MOH) is a clinical concern in the management of migraine headache. MOH arises from the frequent use of medications used for the treatment of a primary headache. Medications that can cause MOH include opioid analgesics as well as formulations designed for the treatment of migraine, such as triptans, ergot alkaloids, or drug combinations that include caffeine and barbiturates. Gathering evidence indicates that migraine patients are more susceptible to development of MOH, and that prolonged use of these medications increases the prognosis for development of chronic migraine, leading to the suggestion that similar underlying mechanisms may drive both migraine headache and MOH. In this review, we examine the link between several mechanisms that have been linked to migraine headache and a potential role in MOH. For example, cortical spreading depression (CSD), associated with migraine development, is increased in frequency with prolonged use of topiramate or paracetamol. Increased CGRP levels in the blood have been linked to migraine and elevated CGRP can be casued by prolonged sumatriptan exposure. Possible mechanisms that may be common to both migraine and MOH include increased endogenous facilitation of pain and/or diminished diminished endogenous pain inhibition. Neuroanatomical pathways mediating these effects are examined.

AB - Medication overuse headache (MOH) is a clinical concern in the management of migraine headache. MOH arises from the frequent use of medications used for the treatment of a primary headache. Medications that can cause MOH include opioid analgesics as well as formulations designed for the treatment of migraine, such as triptans, ergot alkaloids, or drug combinations that include caffeine and barbiturates. Gathering evidence indicates that migraine patients are more susceptible to development of MOH, and that prolonged use of these medications increases the prognosis for development of chronic migraine, leading to the suggestion that similar underlying mechanisms may drive both migraine headache and MOH. In this review, we examine the link between several mechanisms that have been linked to migraine headache and a potential role in MOH. For example, cortical spreading depression (CSD), associated with migraine development, is increased in frequency with prolonged use of topiramate or paracetamol. Increased CGRP levels in the blood have been linked to migraine and elevated CGRP can be casued by prolonged sumatriptan exposure. Possible mechanisms that may be common to both migraine and MOH include increased endogenous facilitation of pain and/or diminished diminished endogenous pain inhibition. Neuroanatomical pathways mediating these effects are examined.

UR - http://www.scopus.com/inward/record.url?scp=80054068170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054068170&partnerID=8YFLogxK

U2 - 10.1177/0333102411402367

DO - 10.1177/0333102411402367

M3 - Article

C2 - 21444643

AN - SCOPUS:80054068170

VL - 31

SP - 851

EP - 860

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 7

ER -